Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
167 hedge funds and large institutions have $1.68B invested in Clovis Oncology, Inc. in 2016 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 48 increasing their positions, 59 reducing their positions, and 34 closing their positions.
63% more call options, than puts
Call options by funds: $69.3M | Put options by funds: $42.5M
19% more capital invested
Capital invested by funds: $1.42B → $1.68B (+$262M)
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
2% more funds holding
Funds holding: 163 → 167 (+4)
19% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 59
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$36.5M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$18M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Millennium Management
New York
|
+$14.5M |
| 5 |
PC
Passport Capital
San Francisco,
California
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$39.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.7M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$28.2M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$23.4M |
| 5 |
Morgan Stanley
New York
|
-$21.3M |
CLVS Hedge Fund Activity: Q4 2016 in Review
167 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2016, worth a combined $1.68B — up 19% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CLVS positions and 34 closed out — a net gain of 4 holders — while 48 added to existing stakes and 59 trimmed.
The largest buyer was State Street, adding an estimated $36.5M. The largest seller was Balyasny Asset Management, cutting an estimated $39.8M.
- 167 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2016, up from 163 in Q3 2016.
- Funds reported $1.68B of Clovis Oncology, Inc. stock for Q4 2016, up 19% quarter-over-quarter.
- 38 funds opened new Clovis Oncology, Inc. positions in Q4 2016 and 34 closed out, a net change of +4 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2016 was State Street, an estimated $36.5M added.
- The largest Clovis Oncology, Inc. seller in Q4 2016 was Balyasny Asset Management, an estimated $39.8M sold.
Based on aggregated 13F filings for Q4 2016.